Imagine your grandpa forgetting where he put a book. Okay\u2014maybe that\u2019s normal. But then he forgets the dinner date you planned together. Then your birthday. Then Christmas. Then every holiday. And finally\u2026 he forgets you.<\/p>\n\n\n\n
Alzheimer\u2019s is often called “the long death”\u2014a slow, heartbreaking unraveling of memory, personality, and self. Over 7 million Americans are living with it, and that number is only growing.<\/p>\n\n\n\n
But here\u2019s the thing: new treatments might help prolong lucidity. The question is\u2014at what cost?<\/p>\n\n\n\n
A new class of Alzheimer\u2019s drugs has hit the market. They\u2019re shiny, high-tech, promising something medicine has long failed to deliver: a weapon against forgetting.<\/p>\n\n\n\n
These aren\u2019t just memory boosters. They aim to slow the biological decay<\/em> of the brain. But here\u2019s the catch: some of them come with a risk of brain bleeding, swelling, or even death.<\/p>\n\n\n\n Yep. We\u2019re talking about drugs like Leqembi (FDA-approved in 2023) that may prolong lucidity<\/em>\u2014but have already been linked to patient deaths during clinical trials.<\/p>\n\n\n\n This is because Leqembi is a medicine that helps clear harmful protein clumps called amyloid from the brain, which are linked to Alzheimer\u2019s disease. Sometimes, as the medicine removes these clumps, small blood vessels in the brain can get weak and leak, causing bleeding or swelling or ARIA.<\/p>\n\n\n\n So here\u2019s the question that cracks the whole thing wide open: If a drug could help you stay \u201cyou\u201d a little longer, but might also end your life early, would you take it?<\/strong> And if you have Alzheimer\u2019s\u2014when your mind is already fading\u2014who<\/em> gets to make that call?<\/p>\n\n\n\n Picture this: it\u2019s 2035. Brain scans are instant. Early-onset Alzheimer\u2019s can be detected in your 40s. You test positive. There\u2019s a drug that could give you 5\u20137 more years of clarity\u2014but 1 in 20 patients die from it.<\/p>\n\n\n\n Your partner wants you to take it. Your adult kids say no. The doctor hands you the consent form. Your mind is slipping, but you still know your own name. Do you sign? Or do you wait and risk losing the ability to decide at all?<\/strong><\/p>\n\n\n\n The Hope Side: \u201cWe\u2019re Buying Time\u201d<\/strong><\/p>\n\n\n\n For some patients, drugs like Lequembi might mean a few more years of recognizing their kids, finishing a memoir, or saying goodbye on their own terms.<\/p>\n\n\n\n As advocates put it: <\/p>\n\n\n\n \u201cEven six months of clarity is worth it.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n The Harm Side: \u201cThe Cure Might Kill\u201d<\/strong><\/p>\n\n\n\n The risk isn\u2019t minor. In trials, 12% to 35%<\/strong> of patients experienced ARIA<\/a>. Some patients died. Others were left with worsened confusion, headaches, seizures.<\/p>\n\n\n\nThe Big What If?<\/h2>\n\n\n\n
The Debate<\/h2>\n\n\n\n
\n